Targeting the Genus Leishmania with Small Molecules
用小分子靶向利什曼原虫属
基本信息
- 批准号:10579191
- 负责人:
- 金额:$ 75.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-24 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AcademiaAddressAdhesivesAdverse effectsAffectAffinityAmericanAmphotericin BAntimonyAntineoplastic AgentsAntiparasitic AgentsBehaviorBiological AssayBiologyBone MarrowBostonCellsChemicalsClinicalCollaborationsCountryCutaneousCutaneous LeishmaniasisDevelopmentDiseaseDoseDrug Delivery SystemsDrug KineticsDrug TargetingExhibitsExperimental ModelsFormulationGeneticGoalsGrantHospitalizationImmune systemIn VitroInfectionKnock-outKnowledgeLaboratory FindingLeadLeishmaniaLeishmania donovaniLeishmaniasisLesionLiverMacrophageMedicalMethodologyMilitary PersonnelMiltefosineModelingMolecular TargetMucocutaneous leishmaniasisMucous MembraneMutationOklahomaOralOrganOrganismOutcomeParasite resistanceParasitesParasitic DiseasesParasitologyPenetrationPersonsPharmaceutical PreparationsPhenotypePhlebotominaePopulationPopulations at RiskPredispositionReagentRegional DiseaseReportingResearchResistanceRouteSand FliesSeriesSkinSpleenStructure-Activity RelationshipTechniquesTeratogensTestingTexasTherapeuticTopical applicationToxic effectUniversitiesValidationVisceralVisceral LeishmaniasisWorkYeastsalternative treatmentanalogbiocompatible polymerchemotherapycytotoxicdeep sequencingdesigndrug candidatedrug discoveryear infectiongenome analysishuman diseaseimprovedin vivoinnovationlead seriesliposomal formulationmembermetermonocytenanomolarneglectnovel therapeuticspharmacologicpre-clinicalprogramsscreeningside effectskin ulcersmall moleculetransmission processvector
项目摘要
PROJECT SUMMARY AND ABSTRACT
Targeting the Genus Leishmania with Small Molecules
Leishmaniasis is a neglected disease caused by protozoan parasites from the genus Leishmania sp. It
is transmitted by the sandfly vector and manifests in different clinical forms including skin ulcers, mucosa
destruction, damage to visceral organs such as the liver and spleen, and bone marrow damage. The clinical
outcome is determined primarily by the species of the parasite and the immune system of the host. There are
98 countries affected by leishmaniasis with more than 2 million people currently infected and 350 million people
at risk. The spread of leishmaniasis is of particular concern to US citizens in southern states such as Texas and
Oklahoma, where cases have recently been reported, as well as to US military troops stationed abroad in
geopolitically unstable regions where the disease tends to thrive.
Chemotherapy options for leishmaniasis are limited. Antimonials have been the first line drug for decades
in most endemic countries, despite antimony’s notorious adverse effects, hospitalization requirements and
increasing cases of antimony-resistant parasites. Amphotericin B, the main alternative treatment, also causes
significant harmful side effects. Liposomal formulations are better tolerated, but are prohibitively expensive for
most affected populations. Miltefosine, an anti-cancer drug, was recently repurposed to treat leishmaniasis and
is the only oral treatment available and approved for use in the US. Miltefosine also has toxicity limitations,
teratogenicity and lack of efficacy against certain Leishmania species. The development of new chemotherapies
to treat the different clinical forms of leishmaniasis is in urgent demand, and is clearly an unmet medical need.
To address this unmet medical need, Scott Schaus and Lauren Brown from Boston University (BU) will
lead a collaborative project with Jair Lage Siqueira-Neto at the UC San Diego Center for Discovery and
Innovation in Parasitic Diseases (CDIPD), Camila Indiani de Oliveira at FIOCRUZ and Mark Grinstaff at BU to
characterize the activity of antileishmanial small molecules and develop them as systemic and topical
therapeutics. Preliminary work by the team has led to the identification of a chemotype with nanomolar in vitro
efficacy against both visceral- and cutaneous-causative species of the parasite, a suitable pharmacokinetic
profile for in vivo studies, and demonstrated in vivo efficacy in a cutaneous leishmaniasis infection model.
This grant outlines a proposal to further develop the chemotype and address specific challenges in
antileishmanial drug discovery, including drug target identification, options for dosing and administration, and
most importantly the applicability of the chemotype to treat multiple manifestations of the disease, including those
that are most relevant and endemic to the American continents. Our end goal is to develop at least one pre-
clinical candidate for the treatment of either visceral or cutaneous leishmaniasis.
项目总结与摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lauren Elaine Brown其他文献
Lauren Elaine Brown的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lauren Elaine Brown', 18)}}的其他基金
Targeting Hsp90 in cryptococcal fungal pathogenesis
隐球菌真菌发病机制中的靶向 Hsp90
- 批准号:
10669803 - 财政年份:2022
- 资助金额:
$ 75.15万 - 项目类别:
Targeting Hsp90 in cryptococcal fungal pathogenesis
隐球菌真菌发病机制中的靶向 Hsp90
- 批准号:
10517704 - 财政年份:2022
- 资助金额:
$ 75.15万 - 项目类别:
Targeting the Genus Leishmania with Small Molecules
用小分子靶向利什曼原虫属
- 批准号:
10377374 - 财政年份:2021
- 资助金额:
$ 75.15万 - 项目类别:
Targeting Hsp90 in cryptococcal fungal pathogenesis
隐球菌真菌发病机制中的靶向 Hsp90
- 批准号:
9171395 - 财政年份:2016
- 资助金额:
$ 75.15万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 75.15万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 75.15万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 75.15万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 75.15万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 75.15万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 75.15万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 75.15万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 75.15万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 75.15万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 75.15万 - 项目类别:
Research Grant